Mitochondria Targeted Pharmaceuticals in Aging Associated Diseases
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 5436
Special Issue Editor
Interests: obesity; diabetes; non-alcoholic fatty liver disease; aging; prenatal stress, age-related macular degeneration; mitochondrial dysfunction; oxidative stress; hypoxia
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Mitochondria are organelles that are now well-acknowledged to govern multiple cellular processes beyond their classical role in energy metabolism. Comprehensive and complicated pathways regulate constant mitochondrial biogenesis, fusion, fission, mitophagy, and other activities to maintain mitochondrial homeostasis, fulfilling the specific demands of different cell types. Though mitochondrial dysfunction and oxidative stress presents as a common cellular abnormality, studies have revealed distinct mitochondrial pathologies underlying different diseases.
In the last decade, studies of mitochondria-targeted interventions against disease pathology have risen rapidly, among which mitochondrial pharmaceuticals represents a major topic. Many agents have been developed which target mitochondrial oxidative phosphorylation, membrane potential, metabolite transport, biogenesis, dynamic, redox state etc. to restore mitochondrial homeostasis in affected tissues. To help advance related research in the field, this Special Issue aims to collect relevant studies focusing on (i) natural compounds and derivatives, (ii) designed compounds, and (iii) mitochondria-targeted delivery systems, to improve pathologies associated with metabolism and aging.
The journal Pharmaceuticals invites experts in the field to contribute to Special issue with both reviews and original research articles related to mitochondria-targeted interventions against diseases associated with metabolism and aging.
Prof. Dr. Zhihui Feng
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mitochondrial dysfunction
- mitophagy
- obesity
- diabetes
- NAFLD
- aging
- cognitive function
